Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	TOTAL TRACEING TOTAL CONTROL OF THE PARTITION OF THE PART
Under the Paperwork Reduction Act of 1995, no persons are req	quired to respond to a collection of information unless it contains a valid OMB control number

Substitute for	or form 14	49A/PTO		Complete if Known			
		Application Number		o To			
INFORMATION DISCLOSURE			ION DISCLOSURE	Filing Date	herewith	38	
STATEMENT BY APPLICANT		First Named Inventor	Chinery	25.			
				Group Art Unit		°5-	
	(use	as man	y sheets as necessary)	Examiner Name		60	
Sheet	1	of	3	Attorney Docket Number	ATH 108 CON1	•	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines, Where		
Initials*	No.	Number	Kind Code (if known)	of Cited Document	of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear		
	AA	5,035,878		Borsch	07-30-1991			
	AB	5,155,250		Parker	10-13-1992			
	AC	5,262,439		Parthasarathy	11-16-1993			
	AD	5,294,430		Borsch	03-15-1994			
	AE	5,608,095		Parker et al.	03-04-1997			

				FOREIG	N PATENT DOCUMENTS	-		
Examiner	Cite	e Foreign Patent Document Kind Code	I Name of Patentee or Applicant I	Date of Publication	. agoo, colaiiiio, aiioo,			
Initials*	No.	Office	Number	(if known)	of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
	AF		WO 95/15760		Merrell Dow Pharm.	06-15-1995		П
	AG		WO 95/26719		Arcturus Pharm.	10-12-1995		П
	AH		WO 93/20691		Tykocinski	10-28-1993	p. 5-8, claim 8	
	Al		WO 95/09365		Univ of NY	04-06-1995		
								П
							1	П
								П
								П
								П
Examine	Γ					Date		
Signature	Э					Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hsould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			- -		Complete if Known	DT.
				Application Number		90,
II.	NFOF	RMAT	ION DISCLOSURE	Filing Date	2/7/01	796 790 1900
STATEMENT BY APPLICANT				First Named Inventor	Chinery	//
				Group Art Unit		60
(use as many sheets as necessary)				Examiner Name		
Sheet	2	of	3	Attorney Docket Number	ATH 108 CON1	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	BA	COFFEY, et al., Cancer Res. 47, 4590 (1987)	
	BB	CROOK, et al. Oncogene 6, 873 (1991)	
	ВС	SCHEFFNER, et al. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88, 5523 (1991)	
	BD	RIPOLL, et al., Vitimin E Enhances the Chemotherapeutic Effects of Adriamycin, <i>Biological Abstracts</i> , 82, 82084938	
	BE	YAUNAGA et al., Vitimin E and Cancer Therapy-Experimental Study in Mice, Database National Cancer Institute, 1982.	
	BF	SZCZEPANSKA et al., Inhibition of Leukocyte Migration by Cancer Chemotherapeutic Agents and its Prevention by Free Radical Scavengers and Thiols, Biological Abstracts Vol. 85, 85106445	
	BG	PRASAD et al., Vitamin E Increases the Growth Inhibitoryuy and Differenciating Effects of Tumor Therapeutic Agents on Neuro Blastoma and Glioma Cells in Culture, Biological Abstracts, vol. 70, 70052454	
	вн	DRAGO, et al., Chemptherapy and Vitamin E in Treatment of NB Rat Prostrate Tumors, Biological Abstracts Vol. 88, 88006807	
	ВІ	CLOOS JACQUELINE JAN, Influence of the antioxidant N-acetylcysteine annd its metabolites on Damge induced by Bleomycin in PM2 Bacteriophage, <i>Biological Abstracts</i> , Vol. 96, 98730849.	
	BJ	RIORDAN et al., Case study: High Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney, <i>J. Orthomolecular Med.</i> , 5:1, 1990, 5-7.	
	ВК	CAMPBELL et al., Retticulum Cell Sarcoma: Two Complete "Spontaneous" Regressions, in Response to High-Dose Ascorbic Acid Therapy, <i>Oncology, 48</i> : 6 (1991), 495-497.	
	BL	BONGERS, Antioxidant-Related Parameters in Patients Treated for Cancer Chemoprevention with Nacetylcysteine, <i>Biological Abstracts</i> , vol. 95, 98363146.	
	ВМ	OFFERMAN, etal. AntooxidantSensitive Regulation of Inflammatory_Response Genes in Kaposi's Sarcoma Cells, <i>J. of AIDS and Hum. Retro.</i> , (1996) 13:1-11.	
	BN	TYAGI S C, Reduction-Oxidation state Regulation of Extracellular Matrix Metalloproteinases and Tissue Inhibitors in Cardiac Normal and Transformed Fibroblast Cells, <i>Biological Abstracts</i> , vol. 96, 98730849.	

Examiner	•	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use unough 10/31/39. ONID 0031-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complet if Known			
				Application Number		
11	NFOF	RMATI	ON DISCLOSURE	Filing Date	2/7/01	
STATEMENT BY APPLICANT				First Named Inventor	Chinery	
				Group Art Unit		
(use as many sheets as necessary)			y sheets as necessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	ATH 108 CON1	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т			
	CA	ROESL, Differential Regulation of the JE Gene Encoding the Monocyte Chemoattractant Protein (MCP-1) in Cerviacl Carcinoma Cells and Derived Hybrids, <i>Biological Abstracts</i> , Vol. 94, 97193049				
	СВ	KOWENS-LEUTZ, et al., Novel Mechanism of C/EPBbeta (NF-M) Transcriptional Control: Activation Through Derepression, <i>Genes and Development</i> , 8:1994, 2781-2791.				
	СС	FAVRE et al., The catalytic Subunit of protein Phophatase 2A is Carboxyl-methylated in vivo, <i>J. of Biol. Chem.</i> , 269:23, (1994), 16311-16317.				
	CD	TRAUTWIEN et al., Protein Kinease A and C Site-Specific Phosphorylations of LAP (nf-IL6) Modulate its Binding Affinity to DNA Recognition Elelments, <i>J. of Clin. Investig.</i> , 93:6, (1994) 2554-2561				
	CE	WPI Derwent Publications Ltd., 97-373441 1995.				
	CF	WPI Derwent Publications Ltd., 96-157002 1996.				
	EA	CHINERY, R. et al. Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein beta Journal of Biological Chemistry 272: 30356-30361 (1997)				
	EB	CHINERY, R. et al. Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein beta Journal of Biological Chemistry 272: 30356-30361 (1997)				
	EC	Berkowitz et al. Tet. Lett. Vol. 35, No. 35, pages 6445-6448 (July 1994)				
	ED	Mahoney et al., J. Biol. Chem. Vol. 267, No. 27 pages 19396-19403 (July 1994)				
	EF	Abstract to Hedricks-Taylor et al. Genomics, Vol. 14(1) pages 12-17 (Jan. 1992)				
+						

Examiner	Dete	
LAGITIMICI	Date	l

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.